News
The Role of Pre-Clinical Bleomycin Models in IPF Drug Development
In this article, TherapeutAix has come together with one of our partners, OracleBio, a provider of Quantitative Digital Pathology services supporting pharma and biotech R&D,
Reflections from ECM2022, Copenhagen, July 2022
The Extracellular Matrix Pharmacology Symposium 2022, aka ECM2022, took place in Copenhagen a couple of weeks ago. The focus of this three-day meeting was very
Join TherapeutAix at the SMR Meeting ‘Innovative New Pharma & Biotech Partnerships’
Darcey Black, Translational Director at TherapeutAix, will be co-organising and attending the ‘Innovative New Pharma and Biotech Partnerships: How is the landscape transforming?’ SMR Meeting
International NASH Day 2022 – Enabling therapies for patients
Non-alcoholic steatohepatitis, or NASH, remains a disease with no approved therapeutics. And it’s been a tough area for drug development, with numerous Phase 2b and
TherapeutAix to present at Extracellular Matrix Pharmacology Congress
TherapeutAix is attending and presenting at the Extracellular Matrix Pharmacology Congress 2022, on 23-25 June at the Tivoli Congress Centre in Copenhagen. The congress will
Workshops reloaded
At TherapeutAix, we have a number of tools to support our clients. In addition to, for example, the MIRIADD approach and our R&D network, we
Rare and common diseases – where’s the link?
It’s Rare Disease Day. Last year on our blog, we looked at how rare diseases can help better our understanding of common diseases. This year,